Codexis, Inc.
A maker of custom-engineered enzymes, Codexis grows proteins in the lab to speed up drug-making and other industrial processes, with uses ranging from pharmaceuticals (including a key ingredient in the cholesterol drug Lipitor) to food and RNA therapies. Born in 2002 as a spin-off from biotech firm Maxygen, the company built its craft on "directed evolution" — mimicking natural selection in a dish to breed better enzymes through its CodeEvolver platform. Its name blends "code" and "exis" (evolution), a nod to the very process that powers it.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| LYTTON LAURENCE W | 13G/APassive | 5.2% | 5.59M | Aug 13, 2026 |
| Telemark Asset Management, LLC | 13GPassive | 7.3% | 7.85M | Jul 29, 2026 |
| Telemark Fund LP | 13GPassive | 7.3% | 7.85M | Jul 29, 2026 |
| Colin S. McNay | 13GPassive | 7.3% | 7.85M | Jul 29, 2026 |
| Aberdeen Group plc | 13G/APassive | 7.45% | 6.77M | Jul 20, 2026 |
| abrdn Inc. | 13G/APassive | 7.45% | 0 | Jul 20, 2026 |
| Opaleye Management Inc. | 13G/APassive | 7.47% | 6.79M | May 5, 2026 |
| James Silverman | 13G/APassive | 7.47% | 6.79M | May 5, 2026 |
| Opaleye, L.P. | 13G/APassive | 7.33% | 6.67M | May 5, 2026 |
| Integrated Core Strategies (US) LLC | 13GPassive | 5.2% | 4.73M | Apr 14, 2026 |